AllVascular | Medical company
AllVascular
Phone: +61 2 9438 5228
Reviews
to load big map
24.01.2022 Delighted that A/Prof Nick Pavlakis will be making a presentation to attendees of the Australian Gastro-Intestinal Trials Group ASM on August 28. The presentation includes an introduction to the Company sponsored clinical study and patient experience with the AVAS device.
22.01.2022 A great honour to welcome these two accomplished ladies - Tsui Lian and Niamh Dempsey to the growing AllVascular team. Tsui is a pharmacist by background and holds an MBA from the University of Adelaide. She joins the team as Chief Marketing Officer after holding senior healthcare marketing roles at General Electric and ResMed. Niamh holds a Masters in Clinical Practice from the University College Dublin. She joins AllVascular as Clinical Support Manager. Niamh has over 16 years experience in oncology nursing management and has been recognised for establishing the Liver and Cancer Services at King Faisal Specialist Hospital & Research Centre.
18.01.2022 AllVascular is pleased to announce that the Company has commenced a capital raise with leading broker Bell Potter in Sydney. The funds raised will be used to support the Company sponsored clinical trials and commercialisation efforts for the AVAS device in Australia and Europe. The Company is targeting an IPO on the ASX in 12 months. https://www.afr.com//medical-device-outfit-allvascular-lau
17.01.2022 Excited to be shortlisted by @MedtronicANZ to present the AVAS technology at Eureka Live, as a part of the @AusBiotech talk series. Register now: https://bit.ly/2WIYHdz to hear our CEO, David Radford, explain the benefits the AVAS provides to patients.
15.01.2022 AllVascular is pleased to announce that it has been provided with $2.4M in non-dilutive capital from NSW Health's Medical Devices Fund. The capital will be used to accelerate the commercialisation of its lead product - the AVAS Arterial Access System for the treatment of solid organ cancers.
11.01.2022 4 balloon catheters inserted via the AVAS to obstruct blood flow to the liver for oxaliplatin infusions. The AVAS accesses the axillary artery in minutes, up to 18Fr through the device's lumen with no arterial punctures or closer required. Come back and do it again in 3 days.
08.01.2022 The Company advises that A/Prof Ho-Shon will be presenting to attendees of this years Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Summit to be held online on September 12-15. A/Prof Ho-Shon will be discussing his experience with the AVAS when treating salvage liver cancer patients and the 47 patient SYS-CAPLIOX clinical trial.
06.01.2022 Welcome to the team Tsui and Niamh! Excited to be working with you to bring the AVAS technology to patients world-wide.
03.01.2022 With COVID-19 restrictions being eased in NSW, AllVascular is pleased to announce that as of last week, further patients have been implanted with the AVAS to facilitate isolated and direct chemotherapy treatments. AllVascular is supporting the oncology and IR teams to accelerate the treatments for patients with secondary liver cancers.
